ReMuS Registry / ReMuS, The Czech Republic Multiple Sclerosis Patient Registry / ReMuS, Registr pacientů s roztroušenou sklerózou

18/02/2026
18/02/2026
Data source
Human
Disease registry
Download as PDF
Population Qualitative Data

Population age groups

  • In utero
  • Paediatric Population (< 18 years)
    • Neonate
      • Preterm newborn infants (0 – 27 days)
      • Term newborn infants (0 – 27 days)
    • Infants and toddlers (28 days – 23 months)
    • Children (2 to < 12 years)
    • Adolescents (12 to < 18 years)
  • Adult and elderly population (≥18 years)
    • Adults (18 to < 65 years)
      • Adults (18 to < 46 years)
      • Adults (46 to < 65 years)
    • Elderly (≥ 65 years)
      • Adults (65 to < 75 years)
      • Adults (75 to < 85 years)
      • Adults (85 years and over)

Estimated percentage of the population covered by the data source in the catchment area

ReMuS covers an estimated ~90% of disease-modifying therapy (DMT)-treated multiple sclerosis (MS) patients in the Czech Republic. All 15 specialised MS centres authorised to prescribe DMTs are contractually anchored within the ReMuS registry network, and DMT initiation in the Czech Republic is restricted to these centres. A cross-validation study comparing ReMuS records against national administrative healthcare data from the Institute of Health Information and Statistics of the Czech Republic (IHIS) for cladribine (Mavenclad®) confirmed a 91.9% overlap of unique patient counts between ReMuS and IHIS reimbursement records for 2023–2024, supporting high population coverage for DMT-treated patients. As of the latest data cut (30 June 2025), ReMuS contains records for approximately 24,000 MS patients, of whom approximately 20,000 is actively followed and ~17,400 are on active DMT. The registry does not systematically capture MS patients who are not treated with DMTs at the specialised centres; however, untreated patients who attend these centres for clinical follow-up are also included (approximately 13% of the registry population).

Description of the population covered by the data source in the catchment area whose data are not collected (e.g., people who are registered only for private care)

The following MS patient subgroups in the Czech Republic may not be fully captured in ReMuS:

(1) Patients diagnosed with MS who have never been referred to any of the 15 specialised MS centres — given that DMT prescribing in the Czech Republic is restricted to these centres, such patients would by definition be untreated and managed solely in general neurological care. While this scenario is unlikely given the standard clinical pathway for MS in the Czech Republic, the registry has no mechanism to identify these individuals;

(2) Patients who declined informed consent for registry participation (estimated <5% of eligible patients at participating centres);

(3) Patients with longstanding progressive MS (e.g. disease onset in the 1990s or earlier) who are no longer within DMT reimbursement criteria and have transitioned from specialised centre follow-up to local neurological care — this group represents a meaningful coverage gap, particularly for studies requiring long-term disability progression data. An ongoing cooperation with the Institute of Health Information and Statistics of the Czech Republic (IHIS), established in mid-2025, is being used to assess and quantify these coverage gaps by comparing ReMuS enrolment against the national population of MS patients identified through administrative health insurance claims data.
Population

Population size

24000

Active population size

20000